European Business
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
European Business
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
European Business
No Result
View All Result
Home < INDUSTRIES Health

CHMP recommends EU approval of Roche’s ENSPRYNG (satralizumab) for adults and adolescents with neuromyelitis optica spectrum disorder (NMOSD)

by Marie Weil
April 26, 2021
A A
Share on LinkedinShare on Twitter
  • If approved, ENSPRYNG will be the first and only treatment available to both adults and adolescents from 12 years of age with anti-aquaporin-4 antibody (AQP4-IgG) seropositive NMOSD in the EU
  • ENSPRYNG is the only subcutaneous treatment option for NMOSD that can be administered at home every four weeks
  • Recommendation is based on results from the two pivotal Phase III SAkuraStar and SAkuraSky studies, in which ENSPRYNG demonstrated robust and sustained efficacy in reducing the risk of relapse and a favourable safety profile
  • NMOSD is a rare, lifelong and debilitating autoimmune disorder of the central nervous system that can cause blindness, muscle weakness and paralysis

Basel, 23 April 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ENSPRYNG® (satralizumab) as the first subcutaneous treatment option for adults and adolescents from 12 years of age living with anti-aquaporin-4 antibody (AQP4-IgG) seropositive neuromyelitis optica spectrum disorder (NMOSD), as a monotherapy or in combination with immunosuppressive therapy (IST). AQP4-IgG are present in around 70-80% of people with NMOSD, who tend to experience a more severe disease course.

NMOSD is a rare, lifelong and debilitating autoimmune disorder of the central nervous system, often misdiagnosed as multiple sclerosis, that primarily damages the optic nerve(s) and spinal cord, causing permanent blindness, muscle weakness and paralysis. The disease is characterised by unpredictable relapses and severe disability often occurs following the first NMOSD attack, accumulating with each subsequent relapse. Preventing these relapses is the primary goal for disease management. ENSPRYNG has been recommended for use in people who have only experienced a single NMOSD attack and adolescents, currently unserved NMOSD populations, as well as those with more advanced disease.

“Today’s positive CHMP opinion is an important step toward bringing ENSPRYNG to people in the EU living with NMOSD who have limited treatment options,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “ENSPRYNG has been shown to reduce the risk of relapse significantly, while also offering a favourable safety profile. Additionally, if approved, ENSPRYNG would be the first and only treatment that can be self-administered subcutaneously at home following appropriate training.”

ENSPRYNG is a humanised monoclonal antibody designed to target and inhibit interleukin-6 (IL-6) receptor activity, believed to play a key role in the inflammation associated with NMOSD. The treatment was designed by Chugai, a member of the Roche Group, using novel recycling antibody technology which, compared to conventional technology, allows for longer duration of antibody circulation and subcutaneous dosing every four weeks after an initial loading dose.

The CHMP recommendation is based on the results of the Phase III SAkuraStar and SAkuraSky studies in which ENSPRYNG showed robust and sustained efficacy results in reducing the risk of relapse and a favourable safety profile in people with AQP4-IgG seropositive NMOSD. A final decision regarding the approval is expected from the European Commission in the near future.

Tags: < Market

Related Industries

Health

Philips launches AI-powered CT system to accelerate routine radiology and high-volume screening programs

May 18, 2023
Health

Siemens Healthineers opens state-of-the-art education and development center in Erlangen, Germany

May 18, 2023
Health

Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology

May 11, 2023
Health

Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentations at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress

May 9, 2023
Health

Changes in Merck Executive Board

May 9, 2023
Health

Health Care Collaboration in Denmark Aims to Reduce Medical Waste

May 9, 2023

KPIT and ZF join hands to promote an independent company “QORIX”

May 5, 2023

...

OPPO Announces Kaká as Global Brand Ambassador for its UEFA Champions League Partnership

May 26, 2023

...

Barclays announces new leadership for Global Equities

May 24, 2023

...

ENGIE inaugurates the biggest agrovoltaic park in Italy, which will help to power Amazon’s operations

May 27, 2023

...

Interview with Nick Hampton, CEO, Tate & Lyle

May 3, 2023

...

Alstom reinforces its leadership team with the appointment of a new Executive Vice President and Chief Financial Officer and a new Chief Human Resources Officer

May 6, 2023

...

MAN to supply eTrucks to Duvenbeck for Volkswagen Group Logistics from 2024 onwards

May 12, 2023

...

RAILPOOL and GIC expand partnership

May 5, 2023

...

Taking paper packaging forward: Henkel and UPM Specialty Papers present recyclable, grease-resistant paper solution

May 12, 2023

...

Arkema acquires Polytec PT, specialized in adhesives for batteries and electronics

May 18, 2023

...

Asia Pacific Business Asia Pacific Business Asia Pacific Business

EUROPEAN BUSINESS is a premier source of corporate news, business information and insights across broad spectrum of industries in Europe and worldwide.  We are one of the members of the Business World Network.

RESOURCES

  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

CONTACT US

EDITORIAL:     editor # european-biz.com

PARTNERSHIP:     partnership # european-biz.com

HUMAN RESOURCE:     hr # european-biz.com

* (replace # with @)

  • Official Site

Copyright © EUROPEAN-BIZ.COM All rights reserved.

No Result
View All Result
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

Copyright © EUROPEAN-BIZ.COM All rights reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist